Just to grab a point made in another thread earlier from T.T...
2. "The independent expert can't possibly have known about the data validation test because that was agreed between Pfizer and ResApp after the independent expert supplied the draft report"
So if this is the case, then are we in a position where the independent valuations report will/should need to revise the recommendations made to s/o ?
(If not, why not ?)
To be a true Independent & 'current valuation' this would be necessary yes?. Therefore why are s/o referencing a past (dismal) recommended price range that's no longer relevant??
Hence - trading halt, update required perhaps ?
RAP Price at posting:
17.5¢ Sentiment: Hold Disclosure: Held
